...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Australian and New Zealand journal of psychiatry >Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
【24h】

Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.

机译：阿米舒必利与奥氮平对印度精神分裂症的治疗：随机对照试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Atypical antipsychotics are increasingly drugs of first choice in schizophrenia. Amisulpride, a new atypical antipsychotic, is reported to be effective for both positive and negative symptoms of schizophrenia in Western countries but Indian experience is limited. The aim of the present study was therefore to conduct a trial of amisulpride versus olanzapine in Indian schizophrenia patients. METHODS: Eighty adult patients of either sex were randomized to receive standard doses of the two drugs orally, in a single blind manner, for 12 weeks, with follow up at 4 and 8 weeks. Effectiveness was assessed by changes in scores on the Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Positive Symptoms (SAPS), Scale for Assessment of Negative Symptoms (SANS), and physician-administered Clinical Global Impression (CGI) scale. Tolerability was assessed by treatment-emergent adverse drug reactions (ADRs). RESULTS: Evaluable were 39 patients on amisulpride and 38 on olanzapine. The groups were comparable at baseline with respect to demographics, illness duration and rating scores. Final BPRS score was lower for olanzapine (33.2 +/- 9.44) than for amisulpride (37.7 +/- 9.67). SAPS and SANS scores and CGI rating improved individually in both arms but remained comparable between groups throughout the study period, but olanzapine reduced SAPS score to a greater extent. ADRs were encountered in 67.5% and 47.5% of patients (p = 0.113) on amisulpride and olanzapine, respectively. Tremor and insomnia were more frequent with amisulpride, while olanzapine caused more weight gain and sedation. No serious ADRs occurred. CONCLUSIONS: Amisulpride, although comparable to olanzapine on some measures, did not match the improvement seen with the latter drug in BPRS and SAPS scores. Despite differences in ADR profiles, overall tolerability was satisfactory for both drugs. In Indian patients, amisulpride should therefore be an alternative to olanzapine to a limited extent, such as when weight gain and sedation are undesirable.
机译：目的：非典型抗精神病药已成为精神分裂症的首选药物。据报道，氨磺必利是一种新型的非典型抗精神病药，在西方国家对精神分裂症的阳性和阴性症状均有效，但印度的经验有限。因此，本研究的目的是在印度精神分裂症患者中进行氨磺必利和奥氮平的试验。方法：将80名男女成年患者随机分组，以单盲方式口服标准剂量的两种药物，持续12周，并在4周和8周随访。通过简短精神病学评定量表（BPRS），阳性症状评估量表（SAPS），阴性症状评估量表（SANS）和医生管理的临床总体印象量表（CGI）的评分变化来评估有效性。通过治疗紧急药物不良反应（ADR）评估耐受性。结果：氨磺必利39例，奥氮平38例。在人口统计学，疾病持续时间和等级评分方面，两组在基线时具有可比性。奥氮平的最终BPRS评分（33.2 +/- 9.44）低于氨磺必利（37.7 +/- 9.67）。在整个研究期间，SAPS和SANS得分和CGI评分在两个方面均分别改善，但在各组之间保持可比性，但是奥氮平在很大程度上降低了SAPS得分。使用氨磺必利和奥氮平的患者分别有67.5％和47.5％（p = 0.113）遇到ADR。氨磺必利引起的震颤和失眠更为频繁，而奥氮平则引起更多的体重增加和镇静作用。没有发生严重的ADR。结论：氨磺必利尽管在某些方面与奥氮平相当，但在BPRS和SAPS评分方面与后者相比没有改善。尽管ADR资料有所不同，但两种药物的总体耐受性仍令人满意。因此，在印度患者中，氨磺必利应在有限的程度上替代奥氮平，例如在不希望体重增加和镇静时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号